Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
ApexOnco Front Page
Recent articles
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.
Any hopes of differentiation could come down to side effects.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
The Breakwater study hits on overall survival with "unprecedented" data.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
